Immunocore advances IMCgp100 into clinical trial
IMCgp100 is the first clinical candidate originating from Immunocore’s ImmTAC technology platform which builds on expertise with T cell receptors and has the potential to target a range
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
Immunovaccine’s DepoVax platform is a lipid depot-based vaccine delivery technology. The primary cell-derived biologic, IRX-2, designed to restore the immune system, seeks to overcome cancer-induced immune suppression and